If Hairgenetix doesn’t deliver results in 4 months, get a full refund in just 3 simple steps.
Trusted by hundreds and rated
With an 'Excellent' rating of 4.6 stars, based on over 1,200 reviews, our customers' trust in Hairgenetix reflects the remarkable results you can achieve with our hair growth products.
Our products are third-party clinically tested
In a 150-day clinical trial involving 30 men and women aged 18–65 with diverse types of hair loss, the Hairgenetix serum achieved a clinically proven 93% reduction in hair shedding.
GHK Peptide Hair Growth Trial: 52–72 Extra Hairs in 6 Months (2016 Study)
Posted by Weon Ju Lee, Do Won Kim et al. on March 05, 2026
Key Findings at a Glance
A topical spray combining GHK peptide with 5-aminolevulinic acid (5-ALA) produced 52–72 extra hairs per cm² in 6 months — while the placebo group gained only 9.6 hairs (p < 0.05). This was a randomised, double-blind, placebo-controlled trial of 45 men with pattern hair loss. The lower dose (50 mg/mL) actually outperformed the higher dose (100 mg/mL) with 71.5 extra hairs vs 52.6 — a 2.38× increase over baseline compared to 1.21× for placebo. Zero adverse events were reported across all three groups over the full 6-month treatment period.
Research Evidence Summary
Condition
Male pattern hair loss (androgenetic alopecia, Norwood-Hamilton II–V)
This article is a plain-language summary of a peer-reviewed scientific study. It is intended to make clinical research more accessible and is not medical advice. Always consult a qualified healthcare professional before starting any new treatment. The original study was conducted independently at Kyungpook National University and is not affiliated with Hairgenetix.
Reviewed by: Esther Bodde — Cosmetic & Medical Doctor (MD)
Why This Research Matters
This is one of the most rigorous clinical trials ever conducted on copper peptides for hair growth. Unlike laboratory studies or reviews, this is a randomised, double-blind, placebo-controlled trial — the gold standard of medical evidence. Forty-five real patients applied a peptide spray daily for 6 months, and the results were compared against a placebo group that didn't know they weren't receiving the active treatment.
The combination of GHK peptide with 5-aminolevulinic acid (5-ALA) is scientifically elegant. As demonstrated in the 2007 Pyo et al. laboratory study, copper peptides stimulate dermal papilla cells and protect them from death. 5-ALA adds a complementary mechanism: it is a precursor to heme (the iron-containing molecule in blood), and prior research showed that 5-ALA with iron stimulates hair growth by enhancing cellular energy production. Combined with GHK peptide, the two compounds target both the energy and growth-signal sides of follicle health.
The fact that patients gained 52–72 extra hairs per cm² with zero side effects — in a properly blinded trial — provides the strongest clinical evidence base for peptide-based hair growth treatments.
What The Researchers Did
The team at Kyungpook National University ran a rigorous clinical trial with three groups:
Study design
Forty-five men aged 20–60 with male pattern hair loss (Norwood-Hamilton II–V) were randomly assigned to one of three groups:
Group A (n=15): ALAVAX 100 mg/mL — the high-dose treatment
Group B (n=14): ALAVAX 50 mg/mL — the low-dose treatment
Group C (n=14): Placebo — identical-looking inactive spray
Application protocol
Patients applied the topical spray once daily before sleep for 6 months. Neither the patients nor the evaluating doctors knew which group was receiving active treatment (double-blind). Hair count, hair length, and hair thickness were measured at baseline, month 1, month 3, and month 6 using trichoscopy.
What is ALAVAX?
ALAVAX is a compound of 5-aminolevulinic acid (5-ALA) and glycyl-histidyl-lysine (GHK) peptide. Chemical formula: C₁₉H₃₁N₇O₆, molecular weight: 453.23, purity >95%. It was applied as a topical spray — a simple, non-invasive daily application.
What Is a Randomised Controlled Trial (RCT)?
A randomised controlled trial is considered the gold standard of clinical evidence. Patients are randomly assigned to either the treatment group or a control (placebo) group. "Randomisation" prevents bias in who receives treatment. "Double-blind" means neither patients nor doctors know who is in which group — eliminating both placebo effects and evaluator bias. "Placebo-controlled" means the control group receives an identical-looking but inactive product, so any improvement in the treatment group can be attributed to the active ingredients rather than the act of applying something.
RCTs are the most reliable way to determine whether a treatment actually works. They sit near the top of the evidence hierarchy, just below meta-analyses (which combine multiple RCTs). The fact that this copper peptide study used an RCT design makes its positive results significantly more meaningful than findings from uncontrolled studies or case reports.
What They Found
71.5 extra hairs per cm² with low-dose treatment (p < 0.05)
Group B (ALAVAX 50 mg/mL) gained an average of 71.5 ± 44.9 additional hairs per cm² over 6 months. This was statistically significant compared to baseline (p < 0.05) and represented a 2.38× increase in hair count — compared to only 1.21× in the placebo group (p < 0.05 for the between-group difference).
52.6 extra hairs per cm² with high-dose treatment (p < 0.05)
Group A (ALAVAX 100 mg/mL) gained 52.6 ± 45.7 additional hairs per cm². While still highly significant versus baseline, the high-dose group actually produced fewer new hairs than the low-dose group — consistent with the biphasic dose-response seen in the 2007 Pyo laboratory study where higher copper peptide concentrations inhibited rather than stimulated growth.
Placebo gained only 9.6 hairs — 5.5× to 7.4× less
The placebo group (Group C) gained only 9.6 ± 45.1 hairs per cm² over 6 months — a change that was not statistically significant. The treatment groups outperformed placebo by 5.5× (Group A) to 7.4× (Group B), providing clear evidence that the improvement was caused by the active ingredients, not the placebo effect.
Results accelerated over time
At month 1, both treatment groups showed modest gains (10.5 and 11.3 hairs) while placebo declined (-3.6). By month 3, Group A reached +54.5 and Group B +37.9 hairs. By month 6, the gains had further accumulated. This pattern of accelerating improvement is consistent with the hair growth cycle — new follicles need multiple growth cycles to produce visible improvement.
Zero adverse events across all groups
No adverse events were reported in any of the three groups over the full 6-month treatment period. This is consistent with the excellent safety profile of copper peptides documented across multiple studies, and is a significant advantage over pharmaceutical treatments like minoxidil (which commonly causes scalp irritation) and finasteride (which carries risk of sexual side effects).
Hair count changes after 6 months of GHK peptide + 5-ALA treatment. Data from Lee et al., Annals of Dermatology (2016). PMID: 27489425.
How This Treatment Works: The Biological Mechanisms
1. GHK peptide — follicle regeneration
GHK (glycyl-histidyl-lysine) is a copper-binding tripeptide that stimulates dermal papilla cell proliferation and protects them from apoptosis. As shown in the 2007 Pyo study, copper peptides reduce the cell death enzyme caspase-3 by 42.7% and shift the Bcl-2/Bax survival balance toward cell protection. The 2018 Pickart review documented that GHK-Cu affects 31.2% of human genes, including collagen synthesis, VEGF production, and TGF-β1 suppression.
2. 5-ALA — cellular energy boost
5-aminolevulinic acid (5-ALA) is a precursor in the heme biosynthesis pathway. Heme is the iron-containing molecule in haemoglobin and mitochondrial cytochromes. By providing excess 5-ALA, the compound boosts mitochondrial energy production in follicle cells — giving them more energy for the metabolically demanding process of hair growth. Previous research showed that 5-ALA with iron directly stimulates hair growth.
3. Synergistic combination
The ALAVAX compound combines these two mechanisms: GHK peptide activates and protects the follicle cells (the "command" side), while 5-ALA enhances their energy supply (the "fuel" side). This dual approach explains why the compound produced stronger results than either ingredient would likely achieve alone.
4. The biphasic dose-response
The finding that 50 mg/mL outperformed 100 mg/mL mirrors what was observed in the laboratory — copper peptides show optimal activity within a specific concentration window. Higher doses can trigger inhibitory feedback. This is an important consideration for product formulation.
Clinical Interpretation
This is gold-standard evidence. A randomised, double-blind, placebo-controlled trial is the highest-quality study design for a single trial. The clear separation between treatment and placebo groups (52–72 vs 9.6 hairs) leaves little room for doubt about efficacy.
The lower dose was more effective — confirming the "sweet spot" principle. Group B (50 mg/mL) gained 71.5 hairs vs Group A's 52.6 hairs (100 mg/mL). This is not a random finding — it's consistent with the biphasic response documented in the 2007 Pyo study. Formulation matters as much as ingredients.
The treatment ratio (2.38×) is a strong effect size. A 2.38-fold increase in hair count ratio versus 1.21 for placebo represents a clinically meaningful difference that patients would notice visually. This is comparable to published results for topical minoxidil in similar populations.
Patient satisfaction was moderate. Despite the objective improvements, only 26.7% (Group A) and 14.3% (Group B) rated results "good" or "excellent." This highlights the gap between measurable hair count increases and subjective satisfaction — patients often need to see dramatic visual change to feel satisfied, which may require longer treatment or combination approaches.
The simple application method is significant. A once-daily topical spray is far more accessible than clinical microneedling procedures. While the 2025 Kuceki study showed stronger results with clinical tattooing (26.5% area regrowth), this trial proves that a simple spray still produces statistically significant improvement.
How This Compares to Other Research
Pyo, Won et al. (2007) — This foundational lab study proved copper peptides (AHK-Cu) stimulate hair follicle growth and protect dermal papilla cells. Lee et al.'s RCT validated these mechanisms in real patients using topical application. Both studies observed the same biphasic dose-response.
Pickart & Margolina (2018) — This comprehensive review explained the gene-level mechanisms behind GHK-Cu's effects. Lee et al. used the same GHK peptide in a clinical formulation, demonstrating that the gene-level changes translate to real-world hair count increases.
Kuceki, Wambier et al. (2025) — This microneedling study combined copper peptides with minoxidil and dutasteride via a tattoo machine, producing 26.5% area regrowth. Lee et al.'s simpler topical approach produced more modest but still significant results — suggesting a spectrum from basic topical use to advanced clinical delivery.
Pamela R.D. (2021) — This placebo-controlled study tested copper tripeptide serum alone, providing a direct comparison point for topical copper peptide efficacy without the 5-ALA component.
Dhurat et al. (2013) — The landmark microneedling study showed that microneedling + minoxidil produced a mean hair count increase of 91.4. Lee et al.'s topical-only approach produced 52–72 new hairs — a somewhat comparable magnitude from a far simpler intervention.
Treatment Protocol
Parameter
Detail
Product
ALAVAX — complex of 5-ALA and GHK peptide (C₁₉H₃₁N₇O₆, MW 453.23, purity >95%)
Concentrations tested
100 mg/mL (Group A) and 50 mg/mL (Group B)
Optimal dose
50 mg/mL — produced more new hairs (71.5) than the 100 mg/mL dose (52.6)
Application
Topical spray applied once daily before sleep
Duration
6 months continuous use
Timeline
Modest gains at month 1 (10–11 hairs); substantial gains by month 3 (38–55 hairs); maximum at month 6
Moderate sample size (n=45). While adequately powered for the primary outcome, 14–15 patients per group is relatively small. Larger trials would provide more precise effect estimates and detect smaller differences between groups.
Hair count increases showed high variability. The standard deviations were large (±44–45 hairs), meaning individual results varied considerably. Some patients likely saw dramatic improvement while others saw less. The mean values are reliable but individual responses will differ.
No comparison to minoxidil or finasteride. The trial compared treatment to placebo only, not to established hair loss treatments. A head-to-head comparison with minoxidil would be valuable for clinical decision-making.
Hair thickness did not change significantly. While hair count increased substantially, hair shaft thickness showed no significant improvement in any group. This suggests the treatment stimulates new hair growth rather than thickening existing hairs.
Patient satisfaction was low relative to objective improvement. Only 14–27% rated results "good" or better, despite statistically significant hair count increases. This may indicate that the visual improvement from hair count alone (without thickness changes) fell short of patient expectations.
6-month duration may not capture full benefit. The accelerating pattern (month 1 < month 3 < month 6) suggests continued improvement beyond 6 months may be possible. Longer studies are needed.
What This Means For Your Hair
Gold-standard evidence that GHK peptide grows new hair — this is not a lab study or a review. Forty-five real men with pattern baldness used a peptide spray daily and grew 52–72 more hairs per cm² than baseline. The placebo group barely changed. That is strong clinical evidence.
The right dose matters more than a higher dose — 50 mg/mL outperformed 100 mg/mL. This "Goldilocks principle" is consistent across copper peptide research and means well-formulated products at optimal concentrations will outperform concentrated products.
Simple daily application works — while clinical microneedling (like the 2025 Kuceki protocol) produces more dramatic results, a basic topical spray applied before bed still produces statistically significant hair growth over 6 months.
Results build over time — most improvement appeared between months 3 and 6. If you start a copper peptide treatment, give it at least 3–6 months before judging results. The hair growth cycle means early gains are small, but they accumulate.
Zero side effects — perhaps the most important finding for daily-use products. No adverse events across 45 patients over 6 months makes copper peptide treatments one of the safest options available for pattern hair loss.
Key Terms Explained
GHK Peptide (Glycyl-Histidyl-Lysine)
A naturally occurring tripeptide that binds copper and stimulates tissue repair. In this study, it was combined with 5-ALA rather than copper directly. Related to GHK-Cu (the copper-bound form) studied in the Pickart & Margolina review.
5-ALA (5-Aminolevulinic Acid)
A naturally occurring amino acid that is a precursor in the heme biosynthesis pathway. It boosts mitochondrial energy production in cells, providing the metabolic fuel needed for hair growth.
Randomised controlled trial (RCT)
The gold standard of clinical evidence. Patients are randomly assigned to treatment or placebo groups, and neither patients nor evaluators know who received which (double-blind). This design minimises bias and provides the most reliable evidence of treatment efficacy.
Norwood-Hamilton Scale
The standard classification system for male pattern baldness, ranging from Type I (no significant loss) to Type VII (extensive loss). Patients in this study ranged from Type II to Type V.
Trichoscopy
A non-invasive diagnostic technique using a specialised microscope (dermoscope) to examine the scalp and hair follicles at high magnification. Used in this study to count hairs per cm² accurately.
Placebo effect
A measurable improvement in patients receiving an inactive treatment, caused by their belief that they are receiving real treatment. The double-blind placebo control in this study eliminates this as an explanation for the results.
Biphasic dose-response
A pattern where a compound stimulates growth at low concentrations but inhibits it at higher concentrations. Seen in this study (50 mg/mL outperformed 100 mg/mL) and in the 2007 Pyo laboratory study.
Frequently Asked Questions
Is this the same as applying copper peptide serum to my scalp?
The active ingredient (GHK peptide) is from the same family, but this study used a specific compound (ALAVAX) that combines GHK with 5-ALA — adding a cellular energy component. Topical copper peptide serums containing GHK-Cu work through similar mechanisms but without the 5-ALA energy boost. Both approaches have evidence supporting them — this RCT provides the strongest clinical evidence, while the 2021 Pamela R.D. study tested copper tripeptide serum specifically.
Why did the lower dose work better than the higher dose?
This is a biphasic (hormetic) dose-response — common with copper peptides and many other biological compounds. The optimal concentration window stimulates maximum growth, while higher concentrations can trigger inhibitory feedback. The 2007 Pyo study documented the same pattern at the cellular level: concentrations above 10⁻⁸ M actually inhibited hair follicle growth. This is why well-formulated products with precise concentrations matter more than simply "more copper peptide."
How does 52–72 new hairs per cm² compare to minoxidil?
Published studies on topical minoxidil typically report increases of 12–25 hairs per cm² over similar treatment periods. The 52–72 hairs in this study significantly exceeds those numbers, though direct comparison requires caution because patient populations, measurement methods, and baseline conditions differ. The Dhurat 2013 study reported 91.4 new hairs with microneedling + minoxidil — suggesting that combining delivery methods produces the strongest results.
Can women use this treatment?
This study included only male patients with male pattern hair loss. Female pattern hair loss has different hormonal mechanisms, and the efficacy of ALAVAX in women has not been tested. However, the underlying mechanisms (DPC stimulation, cellular energy enhancement) are not sex-specific, so there is biological plausibility. Copper peptide serums are generally considered safe for both men and women.
Why was patient satisfaction low despite good hair count results?
Hair count increased significantly but hair thickness did not change. This means patients grew new, potentially fine hairs that added density but not necessarily the visual "fullness" patients expect. Additionally, hair growth is gradual, and some patients may not perceive changes that are measurable under trichoscopy. Combining peptide treatment with approaches that increase hair thickness (like microneedling) may produce more satisfying visual results.
How long do I need to use it before seeing results?
The study measured hair at 1, 3, and 6 months. At month 1, improvement was minimal (~10 hairs). By month 3, significant gains appeared (38–55 hairs). By month 6, results were at their strongest (52–72 hairs). Most experts recommend committing to at least 3–6 months of consistent daily use before evaluating whether a hair treatment is working for you.
Can I combine this with microneedling for better results?
The principle of combining copper peptides with microneedling is strongly supported by research. The 2025 Kuceki study showed that microneedling-delivered copper peptides produced 26.5% scalp area regrowth. While that study used a clinical-grade tattoo machine, at-home dermarolling (0.5–1.5 mm) with a copper peptide serum follows the same principle of enhanced delivery to the follicle.
Is ALAVAX available to buy?
ALAVAX was a specific research compound used in this clinical trial. It is not widely available as a consumer product. However, topical products containing GHK-Cu (the copper-bound form of the same GHK peptide) are commercially available and work through the same follicle-stimulating mechanisms documented in this and other copper peptide studies.
Original Study Reference
Lee WJ, Sim HB, Jang YH, Lee SJ, Kim DW, Yim SH. Efficacy of a Complex of 5-Aminolevulinic Acid and Glycyl-Histidyl-Lysine Peptide on Hair Growth. Annals of Dermatology. 2016;28(4):438–443. doi:10.5021/ad.2016.28.4.438. PMID: 27489425. PMCID: PMC4969472.
How to Cite This Research Summary
Hairgenetix Research Team. "GHK Peptide Hair Growth Trial: 52–72 Extra Hairs in 6 Months (2016 Study)." Hairgenetix Research Library, March 2026.
Available at: https://hairgenetix.com/blogs/articles/ghk-peptide-ala-hair-growth-clinical-trial-2016
Hairgenetix Research Library — We publish plain-language summaries of peer-reviewed clinical studies on hair growth science. Every article links directly to the original published research. Our goal is to make hair loss science accessible, transparent, and evidence-based. Browse all research summaries →
Advanced Daily Scalp Therapy for Stronger, Healthier Hair
🎯 Designed for hair loss and weak, thinning hair 🔬 Clinically Proven Ingredients 💧 Lightweight, non-greasy for easy daily use
The Hairgenetix Copper Peptide Serum is a powerful daily scalp treatment designed to stimulate hair follicles, reduce shedding, and support long-term hair health. Infused with 10% GHK-Cu and 5% AHK-Cu copper peptides, this advanced formula works at the root level to improve follicle longevity, boost collagen production, and enhance scalp circulation—creating the perfect environment for thicker, healthier hair growth.
🚀 Stimulates Hair Growth at the Follicle Level 🛡️ Reduces Hair Shedding & Strengthens Roots 🌿 Improves Scalp Health for Thicker, Healthier Hair
Advanced hair care powered by GHK-Cu copper peptides. This professional shampoo gently cleanses while supporting scalp regeneration, follicle health, and stronger hair growth. Designed to help reduce shedding, improve hair density, and create the optimal environment for healthier, thicker-looking hair with every wash.
Advanced conditioning powered by GHK-Cu copper peptides. This professional conditioner deeply nourishes the hair and scalp while supporting follicle health, strength, and resilience. Designed to reduce breakage, improve hair texture and density, and leave hair stronger, smoother, and healthier-looking with every use.
Professional GHK-Cu Complete Follicle & Scalp Activation System
🚀 Maximizes Hair Growth Support at the Follicle Level 🛡️ Reduces Shedding While Strengthening Hair from Root to Tip 🌿 Optimizes Scalp Health for Thicker, Fuller-Looking Hair
Advanced hair care powered by GHK-Cu copper peptides. This professional shampoo and conditioner set works synergistically to cleanse, nourish, and strengthen the scalp and hair while supporting follicle regeneration and long-term hair growth. Designed to help reduce shedding, improve hair density, and create the optimal environment for healthier, thicker-looking hair with consistent use.
Professional GHK-Cu Complete Follicle & Scalp Activation System
🚀 Maximizes Hair Growth Support at the Follicle Level 🛡️ Reduces Shedding While Strengthening Hair from Root to Tip 🌿 Optimizes Scalp Health for Thicker, Fuller-Looking Hair
Advanced hair care powered by GHK-Cu & AHK-Cu Copper Peptides. This professional shampoo, conditioner, and serum set works synergistically to cleanse, nourish, and activate the hair follicles at the root. The shampoo gently removes buildup and prepares the scalp, the conditioner restores moisture and resilience, and the targeted serum delivers concentrated copper peptides directly to the follicle environment. Designed to help reduce shedding, improve hair density, and create optimal conditions for healthier, thicker-looking hair with consistent use.
GHK Peptide Hair Growth Trial: 52–72 Extra Hairs in 6 Months (2016 Study)
Research Evidence Summary
Why This Research Matters
This is one of the most rigorous clinical trials ever conducted on copper peptides for hair growth. Unlike laboratory studies or reviews, this is a randomised, double-blind, placebo-controlled trial — the gold standard of medical evidence. Forty-five real patients applied a peptide spray daily for 6 months, and the results were compared against a placebo group that didn't know they weren't receiving the active treatment.
The combination of GHK peptide with 5-aminolevulinic acid (5-ALA) is scientifically elegant. As demonstrated in the 2007 Pyo et al. laboratory study, copper peptides stimulate dermal papilla cells and protect them from death. 5-ALA adds a complementary mechanism: it is a precursor to heme (the iron-containing molecule in blood), and prior research showed that 5-ALA with iron stimulates hair growth by enhancing cellular energy production. Combined with GHK peptide, the two compounds target both the energy and growth-signal sides of follicle health.
The fact that patients gained 52–72 extra hairs per cm² with zero side effects — in a properly blinded trial — provides the strongest clinical evidence base for peptide-based hair growth treatments.
What The Researchers Did
The team at Kyungpook National University ran a rigorous clinical trial with three groups:
Study design
Forty-five men aged 20–60 with male pattern hair loss (Norwood-Hamilton II–V) were randomly assigned to one of three groups:
Application protocol
Patients applied the topical spray once daily before sleep for 6 months. Neither the patients nor the evaluating doctors knew which group was receiving active treatment (double-blind). Hair count, hair length, and hair thickness were measured at baseline, month 1, month 3, and month 6 using trichoscopy.
What is ALAVAX?
ALAVAX is a compound of 5-aminolevulinic acid (5-ALA) and glycyl-histidyl-lysine (GHK) peptide. Chemical formula: C₁₉H₃₁N₇O₆, molecular weight: 453.23, purity >95%. It was applied as a topical spray — a simple, non-invasive daily application.
What Is a Randomised Controlled Trial (RCT)?
A randomised controlled trial is considered the gold standard of clinical evidence. Patients are randomly assigned to either the treatment group or a control (placebo) group. "Randomisation" prevents bias in who receives treatment. "Double-blind" means neither patients nor doctors know who is in which group — eliminating both placebo effects and evaluator bias. "Placebo-controlled" means the control group receives an identical-looking but inactive product, so any improvement in the treatment group can be attributed to the active ingredients rather than the act of applying something.
RCTs are the most reliable way to determine whether a treatment actually works. They sit near the top of the evidence hierarchy, just below meta-analyses (which combine multiple RCTs). The fact that this copper peptide study used an RCT design makes its positive results significantly more meaningful than findings from uncontrolled studies or case reports.
What They Found
Group B (ALAVAX 50 mg/mL) gained an average of 71.5 ± 44.9 additional hairs per cm² over 6 months. This was statistically significant compared to baseline (p < 0.05) and represented a 2.38× increase in hair count — compared to only 1.21× in the placebo group (p < 0.05 for the between-group difference).
Group A (ALAVAX 100 mg/mL) gained 52.6 ± 45.7 additional hairs per cm². While still highly significant versus baseline, the high-dose group actually produced fewer new hairs than the low-dose group — consistent with the biphasic dose-response seen in the 2007 Pyo laboratory study where higher copper peptide concentrations inhibited rather than stimulated growth.
The placebo group (Group C) gained only 9.6 ± 45.1 hairs per cm² over 6 months — a change that was not statistically significant. The treatment groups outperformed placebo by 5.5× (Group A) to 7.4× (Group B), providing clear evidence that the improvement was caused by the active ingredients, not the placebo effect.
At month 1, both treatment groups showed modest gains (10.5 and 11.3 hairs) while placebo declined (-3.6). By month 3, Group A reached +54.5 and Group B +37.9 hairs. By month 6, the gains had further accumulated. This pattern of accelerating improvement is consistent with the hair growth cycle — new follicles need multiple growth cycles to produce visible improvement.
No adverse events were reported in any of the three groups over the full 6-month treatment period. This is consistent with the excellent safety profile of copper peptides documented across multiple studies, and is a significant advantage over pharmaceutical treatments like minoxidil (which commonly causes scalp irritation) and finasteride (which carries risk of sexual side effects).
How This Treatment Works: The Biological Mechanisms
1. GHK peptide — follicle regeneration
GHK (glycyl-histidyl-lysine) is a copper-binding tripeptide that stimulates dermal papilla cell proliferation and protects them from apoptosis. As shown in the 2007 Pyo study, copper peptides reduce the cell death enzyme caspase-3 by 42.7% and shift the Bcl-2/Bax survival balance toward cell protection. The 2018 Pickart review documented that GHK-Cu affects 31.2% of human genes, including collagen synthesis, VEGF production, and TGF-β1 suppression.
2. 5-ALA — cellular energy boost
5-aminolevulinic acid (5-ALA) is a precursor in the heme biosynthesis pathway. Heme is the iron-containing molecule in haemoglobin and mitochondrial cytochromes. By providing excess 5-ALA, the compound boosts mitochondrial energy production in follicle cells — giving them more energy for the metabolically demanding process of hair growth. Previous research showed that 5-ALA with iron directly stimulates hair growth.
3. Synergistic combination
The ALAVAX compound combines these two mechanisms: GHK peptide activates and protects the follicle cells (the "command" side), while 5-ALA enhances their energy supply (the "fuel" side). This dual approach explains why the compound produced stronger results than either ingredient would likely achieve alone.
4. The biphasic dose-response
The finding that 50 mg/mL outperformed 100 mg/mL mirrors what was observed in the laboratory — copper peptides show optimal activity within a specific concentration window. Higher doses can trigger inhibitory feedback. This is an important consideration for product formulation.
Clinical Interpretation
How This Compares to Other Research
Treatment Protocol
Research Limitations
What This Means For Your Hair
Key Terms Explained
Frequently Asked Questions
Is this the same as applying copper peptide serum to my scalp?
The active ingredient (GHK peptide) is from the same family, but this study used a specific compound (ALAVAX) that combines GHK with 5-ALA — adding a cellular energy component. Topical copper peptide serums containing GHK-Cu work through similar mechanisms but without the 5-ALA energy boost. Both approaches have evidence supporting them — this RCT provides the strongest clinical evidence, while the 2021 Pamela R.D. study tested copper tripeptide serum specifically.
Why did the lower dose work better than the higher dose?
This is a biphasic (hormetic) dose-response — common with copper peptides and many other biological compounds. The optimal concentration window stimulates maximum growth, while higher concentrations can trigger inhibitory feedback. The 2007 Pyo study documented the same pattern at the cellular level: concentrations above 10⁻⁸ M actually inhibited hair follicle growth. This is why well-formulated products with precise concentrations matter more than simply "more copper peptide."
How does 52–72 new hairs per cm² compare to minoxidil?
Published studies on topical minoxidil typically report increases of 12–25 hairs per cm² over similar treatment periods. The 52–72 hairs in this study significantly exceeds those numbers, though direct comparison requires caution because patient populations, measurement methods, and baseline conditions differ. The Dhurat 2013 study reported 91.4 new hairs with microneedling + minoxidil — suggesting that combining delivery methods produces the strongest results.
Can women use this treatment?
This study included only male patients with male pattern hair loss. Female pattern hair loss has different hormonal mechanisms, and the efficacy of ALAVAX in women has not been tested. However, the underlying mechanisms (DPC stimulation, cellular energy enhancement) are not sex-specific, so there is biological plausibility. Copper peptide serums are generally considered safe for both men and women.
Why was patient satisfaction low despite good hair count results?
Hair count increased significantly but hair thickness did not change. This means patients grew new, potentially fine hairs that added density but not necessarily the visual "fullness" patients expect. Additionally, hair growth is gradual, and some patients may not perceive changes that are measurable under trichoscopy. Combining peptide treatment with approaches that increase hair thickness (like microneedling) may produce more satisfying visual results.
How long do I need to use it before seeing results?
The study measured hair at 1, 3, and 6 months. At month 1, improvement was minimal (~10 hairs). By month 3, significant gains appeared (38–55 hairs). By month 6, results were at their strongest (52–72 hairs). Most experts recommend committing to at least 3–6 months of consistent daily use before evaluating whether a hair treatment is working for you.
Can I combine this with microneedling for better results?
The principle of combining copper peptides with microneedling is strongly supported by research. The 2025 Kuceki study showed that microneedling-delivered copper peptides produced 26.5% scalp area regrowth. While that study used a clinical-grade tattoo machine, at-home dermarolling (0.5–1.5 mm) with a copper peptide serum follows the same principle of enhanced delivery to the follicle.
Is ALAVAX available to buy?
ALAVAX was a specific research compound used in this clinical trial. It is not widely available as a consumer product. However, topical products containing GHK-Cu (the copper-bound form of the same GHK peptide) are commercially available and work through the same follicle-stimulating mechanisms documented in this and other copper peptide studies.
How to Cite This Research Summary
Hairgenetix Research Team. "GHK Peptide Hair Growth Trial: 52–72 Extra Hairs in 6 Months (2016 Study)." Hairgenetix Research Library, March 2026.
Available at: https://hairgenetix.com/blogs/articles/ghk-peptide-ala-hair-growth-clinical-trial-2016
Related Research on Hairgenetix